{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-007715","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2026-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.020575+00:00","generated_at":"2026-05-16T02:58:01.124430+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vistagen Q3 FY2026 net loss $18.9M; PALISADE-4 topline expected H1 2026","bullets":["Net loss $18.9M for quarter ended Dec 31, 2025, vs $14.1M a year ago; R&D expense $14.2M, G&A $5.6M.","Cash and equivalents $61.8M as of Dec 31, 2025; company targeting disciplined capital allocation.","PALISADE-4 Phase 3 trial of fasedienol for social anxiety ongoing; topline results from randomized portion expected H1 2026.","Previous PALISADE-3 Phase 3 missed primary endpoint in Dec 2025; safety data favorable.","Appointed Nick Tressler as CFO in Dec 2025; refisolone IND submission for hot flashes planned H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-007715","json":"https://secwatch.observer/filing/0001628280-26-007715.json","markdown":"https://secwatch.observer/filing/0001628280-26-007715.md","text":"https://secwatch.observer/filing/0001628280-26-007715.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026007715/0001628280-26-007715-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026007715/vtgn-20260212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:58:01.124430+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}